ArticleQJM : monthly journal of the Association of Physicians2026
Case report: CNS tuberculoma in a patient with prior pulmonary tuberculosis.
Article in QJM : monthly journal of the Association of Physicians, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) tuberculoma is a rare but severe form of tuberculosis (TB) that can mimic other neurological disorders and poses major diagnostic challenges, especially with drug resistance. We report a case of a woman in her 60s who developed CNS tuberculoma four years after completing anti-tuberculosis therapy (ATT) for pulmonary TB. She presented with progressive left-sided weakness, facial asymmetry, and dysphagia. MRI revealed a ring-enhancing lesion in the right caudate nucleus with a lipid-lactate peak on spectroscopy, consistent with tuberculoma. Drug susceptibility testing confirmed resistance to isoniazid and rifampicin, indicating multidrug-resistant TB (MDR-TB). A modified regimen with levofloxacin, ethionamide, and para-aminosalicylic acid led to neurological recovery. This case underscores the importance of considering CNS tuberculoma in patients with neurological deficits and prior TB, even after apparent cure. Early neuroimaging, drug resistance testing, and individualized therapy are vital to improving outcomes and reducing morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.